CTA
SRPT icon

Colonial Trust Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Colonial Trust Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.6K Hold
700
– – ﹤0.01% 537
2026
Q1 		$15.2K Buy
700
+200
+40% +$3.87K ﹤0.01% 474
2025
Q4 		$10.8K Buy
500
+100
+25% +$2.11K ﹤0.01% 503
2025
Q3 		$7.71K Buy
400
+200
+100% +$3.56K ﹤0.01% 529
2025
Q2 		$3.42K Buy
200
+150
+300% +$6.4K ﹤0.01% 614
2025
Q1 		$3.19K Buy
+50
New +$5.26K ﹤0.01% 602

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Colonial Trust Advisors's SRPT Position: Q2 2026 in Review

Colonial Trust Advisors held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 700 shares worth $12.6K. The position accounts for ﹤0.01% of the portfolio, ranked #537.

Colonial Trust Advisors first reported a position in SRPT in Q1 2025 and has held it in 6 quarters since. The position peaked at $15.2K in Q1 2026. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Colonial Trust Advisors held 700 shares of Sarepta Therapeutics worth $12.6K as of Q2 2026.
  • Colonial Trust Advisors left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Colonial Trust Advisors's portfolio in Q2 2026, its #537 holding.
  • Colonial Trust Advisors first reported a position in Sarepta Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Colonial Trust Advisors's Sarepta Therapeutics position peaked at $15.2K in Q1 2026.
  • 324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Colonial Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.